Zantac pills for stomach acid
Sanofi said Wednesday it had reached an agreement in principle to settle 4,000 disputes relating to Zantac, a treatment for stomach acid accused of being carcinogenic.
Sanofi did not disclose the financial terms of the agreement, which has yet to be finalized.
This agreement is expected to resolve most pending litigation in the United States, with the exception of legal actions filed in the state of Delaware.
Sanofi said it had reached an agreement in particular to avoid a costly procedure. The group specified in the agreement that it disclaimed any responsibility in the matter.
(Dietrich Knauth; French version Camille Raynaud)